Lite Strategy (LITS) Non Operating Interest Expenses (2018 - 2020)
Lite Strategy (LITS) posted Non Operating Interest Expenses of $5000.0 for Q3 2020, down 64.29% on a QoQ basis from $14000.0 in Q3 2019, and down 64.29% year-over-year from $14000.0 in Q4 2019.
Powered by 
Analysis
Lite Strategy (LITS) Non Operating Interest Expenses (2018 - 2020) Analysis & Trends
Lite Strategy has reported Non Operating Interest Expenses for 3 years, with the latest figure at $5000.0 in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2020 | 5,000.00 |
| Sep 30, 2019 | 14,000.00 |
| Sep 30, 2018 | 1,000.00 |